Table A1.
Clinical Characteristics of Included and Excluded Patients With MPNs Who Developed AML/MDS
| Characteristic | Included |
Excluded |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| Total No. of patients | 162 | 100 | 44 | 100 |
| Sex | ||||
| Female | 67 | 41 | 21 | 48 |
| Male | 95 | 59 | 23 | 52 |
| MPN subtype | ||||
| PV | 110 | 68 | 30 | 68 |
| ET | 26 | 16 | 7 | 16 |
| PMF | 15 | 9 | 4 | 9 |
| MPN NOS | 11 | 7 | 3 | 7 |
| Age at MPN diagnosis, years | ||||
| < 49 | 17 | 10 | 10 | 22 |
| 50-59 | 35 | 22 | 9 | 20 |
| 60-69 | 55 | 34 | 12 | 27 |
| > 70 | 55 | 34 | 13 | 30 |
| Calendar period of MPN diagnosis | ||||
| 1958-1969 | 32 | 20 | 10 | 23 |
| 1970-1979 | 23 | 14 | 10 | 23 |
| 1980-1989 | 41 | 25 | 10 | 23 |
| 1990-1999 | 51 | 31 | 11 | 25 |
| 2000-2005 | 15 | 9 | 3 | 7 |
| Treatment | ||||
| None | 41 | 25 | 7 | 16 |
| Alk only | 12 | 7 | 9 | 20 |
| P32 only | 39 | 24 | 8 | 18 |
| HU only | 34 | 21 | 9 | 20 |
| Alk + P32 | 19 | 12 | 4 | 9 |
| Alk + HU | 5 | 3 | 4 | 9 |
| HU + P32 | 10 | 6 | 2 | 5 |
| Alk + P32 + HU | 2 | 1 | 1 | 2 |
NOTE. Included patients had available matched controls; patients were excluded because of lack of available matched controls.
Abbreviations: Alk, alkylating agent; AML, acute myeloid leukemia; ET, essential thrombocythemia; HU, hydroxyurea; MDS, myelodysplastic syndrome; MPN, chronic myeloproliferative neoplasm; NOS, not otherwise specified; P32, radioactive phosphorus; PMF, primary myelofibrosis; PV, polycythemia vera.